Your browser doesn't support javascript.
loading
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
Im, Annie; Rashidi, Armin; Wang, Tao; Hemmer, Michael; MacMillan, Margaret L; Pidala, Joseph; Jagasia, Madan; Pavletic, Steven; Majhail, Navneet S; Weisdorf, Daniel; Abdel-Azim, Hisham; Agrawal, Vaibhav; Al-Homsi, A Samer; Aljurf, Mahmoud; Askar, Medhat; Auletta, Jeffery J; Bashey, Asad; Beitinjaneh, Amer; Bhatt, Vijaya Raj; Byrne, Michael; Cahn, Jean-Yves; Cairo, Mitchell; Castillo, Paul; Cerny, Jan; Chhabra, Saurabh; Choe, Hannah; Ciurea, Stefan; Daly, Andrew; Perez, Miguel Angel Diaz; Farhadfar, Nosha; Gadalla, Shahinaz M; Gale, Robert; Ganguly, Siddhartha; Gergis, Usama; Hanna, Rabi; Hematti, Peiman; Herzig, Roger; Hildebrandt, Gerhard C; Lad, Deepesh P; Lee, Catherine; Lehmann, Leslie; Lekakis, Lazaros; Kamble, Rammurti T; Kharfan-Dabaja, Mohamed A; Khandelwal, Pooja; Martino, Rodrigo; Murthy, Hemant S; Nishihori, Taiga; O'Brien, Tracey A; Olsson, Richard F.
Afiliación
  • Im A; University of Pittsburgh/UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Rashidi A; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • Wang T; Department of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Hemmer M; Department of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin.
  • MacMillan ML; Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.
  • Pidala J; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Jagasia M; Vanderbilt University Medical Center, Nashville, Tennessee.
  • Pavletic S; Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Majhail NS; Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.
  • Weisdorf D; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • Abdel-Azim H; (0)Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California.
  • Agrawal V; Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Al-Homsi AS; (2)New York University Langone Medical Center, New York, New York.
  • Aljurf M; (3)Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
  • Askar M; (4)Department of Pathology and Laboratory Medicine, Baylor University Medical Center, Dallas, Texas.
  • Auletta JJ; (5)Blood and Marrow Transplant Program and Host Defense Program, Divisions of Hematology/Oncology/Bone Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio.
  • Bashey A; (6)Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia.
  • Beitinjaneh A; (7)Department of Hematology and Oncology, University of Miami, Miami, Florida.
  • Bhatt VR; (8)The Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.
  • Byrne M; Vanderbilt University Medical Center, Nashville, Tennessee.
  • Cahn JY; Department of Hematology, CHU Grenoble Alpes, Grenoble, France.
  • Cairo M; (0)Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, New York.
  • Castillo P; (1)UF Health Shands Children's Hospital, Gainesville, Florida.
  • Cerny J; Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.
  • Chhabra S; Department of Medicine, Medical College of Wisconsin, CIBMTR® (Center for International Blood and Marrow Transplant Research), Milwaukee, Wisconsin.
  • Choe H; (3)James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Ciurea S; (4)The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daly A; (5)Tom Baker Cancer Center, Calgary, Alberta, Canada.
  • Perez MAD; (6)Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain.
  • Farhadfar N; (7)Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.
  • Gadalla SM; (8)Division of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, Maryland.
  • Gale R; Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom.
  • Ganguly S; (0)Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas.
  • Gergis U; (1)Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania.
  • Hanna R; (2)Cleveland Clinic Foundation, Cleveland, Ohio.
  • Hematti P; Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, Wisconsin.
  • Herzig R; (4)University of Kentucky Chandler Medical Center, Louisville, Kentucky.
  • Hildebrandt GC; (5)Markey Cancer Center, University of Kentucky, Lexington, Kentucky.
  • Lad DP; (6)Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Lee C; (7)Utah Blood and Marrow Transplant Program at Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Lehmann L; (8)Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts.
  • Lekakis L; (7)Department of Hematology and Oncology, University of Miami, Miami, Florida.
  • Kamble RT; Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.
  • Kharfan-Dabaja MA; (0)Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
  • Khandelwal P; (1)Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; (2)Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio.
  • Martino R; (3)Divison of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Murthy HS; (0)Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
  • Nishihori T; Department of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, Florida.
  • O'Brien TA; (5)Blood & Marrow Transplant Program, Kids Cancer Centre, Sydney Children's Hospital, Sydney, Australia.
  • Olsson RF; (6)Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; (7)Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
Biol Blood Marrow Transplant ; 26(8): 1459-1468, 2020 08.
Article en En | MEDLINE | ID: mdl-32434056
ABSTRACT
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus <29 years) was significantly associated with higher rates of grade 2 to 4 acute GVHD (hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.11 to 2.12; P = .01). In contrast, PB compared to BM as a stem cell source was a significant risk factor for the development of chronic GVHD (HR, 1.70; 95% CI, 1.11 to 2.62; P = .01) in the RIC setting. There were no differences in relapse or overall survival between groups. Donor age and graft source are risk factors for acute and chronic GVHD, respectively, after PTCy-based haplo-HCT. Our results indicate that in RIC haplo-HCT, the risk of chronic GVHD is higher with PB stem cells, without any difference in relapse or overall survival.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Límite: Adult / Humans Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Límite: Adult / Humans Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2020 Tipo del documento: Article